The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 24, 2012
Filed:
Jul. 19, 2005
José María Estrela Ariquel, Valencia, ES;
Gregorio Asensio Aguilar, Valencia, ES;
Miguel Angel Asensi Miralles, Valencia, ES;
Elena Obrador Plá, Valencia, ES;
Maria Teresa Varea Muñoz, Valencia, ES;
Leonardo Jordá Quilis, Valencia, ES;
Paula Ferrer Pastor, Valencia, ES;
Ramón Segarra Guerrero, Valencia, ES;
Angel Ortega Valero, Valencia, ES;
Maria Benlloch Garcia, Valencia, ES;
José María Estrela Ariquel, Valencia, ES;
Gregorio Asensio Aguilar, Valencia, ES;
Miguel Angel Asensi Miralles, Valencia, ES;
Elena Obrador Plá, Valencia, ES;
Maria Teresa Varea Muñoz, Valencia, ES;
Leonardo Jordá Quilis, Valencia, ES;
Paula Ferrer Pastor, Valencia, ES;
Ramón Segarra Guerrero, Valencia, ES;
Angel Ortega Valero, Valencia, ES;
Maria Benlloch Garcia, Valencia, ES;
Universitat de Valencia, Valencia, ES;
Abstract
The invention relates to the combined use of pterostilbene and quercetin for the production of cancer treatment medicaments. The in vitro growth of melanoma cells B16-F10 (B16M-F10) is inhibited (56%) by combined exposures of short duration (60 min/day) to PTER (40 μM)+QUER(20 μM) (˜average values of plasma concentrations measured within the first hour following the IV administration of 20 mg of each polyphenol/kg ˜). The combined intravenous administration of PTER+QUER (20 mg/kg× day) to mice inhibits (73%) the metastatic growth of melanoma B16M-F10 in the liver, a common site for metastasis development. The invention demonstrates that the combination of PTER+QUER inhibits the growth of malignant melanoma metastasis and prolongs the survival of the carrier host.